<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01496170</url>
  </required_header>
  <id_info>
    <org_study_id>P07820</org_study_id>
    <secondary_id>MK-8931-010</secondary_id>
    <nct_id>NCT01496170</nct_id>
  </id_info>
  <brief_title>A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])</brief_title>
  <official_title>A Study to Assess the Safety, Tolerability, and Pharmacodynamics of MK-8931/SCH 900931 in Patients With Alzheimer's Disease [Phase 1b; Protocol No. 010-00 (Also Known as P07820)]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and pharmacodynamics of three different doses of MK-8931, a
      ß-secretase inhibitor, in participants with mild to moderate Alzheimer's Disease (AD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean population Inhibitory Concentration for 50% Effect (IC50) in cerebral spinal fluid (CSF) ß-amyloid peptide 40 (Aß40)</measure>
    <time_frame>Hour 0 (predose) to 36 hours post-dose on Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in CSF Aß40 concentration determined by time-weighted average from 0 to 24 hours (TWA0-24)</measure>
    <time_frame>Baseline, and assessment over 24 hours post Day 7 dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CSF soluble amyloid precursor protein ß (sAPPß ) concentration determined by TWA0-24</measure>
    <time_frame>Baseline, and assessment over 24 hours post Day 7 dose</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Treatment A: MK-8931 12 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receiving 12 mg MK-8931 for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: MK-8931 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receiving MK-8931 40 mg for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C: Placebo matching MK-8931 12 mg or 40 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receiving placebo matching MK-8931 12 mg or 40 mg for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D: MK-8931 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant receiving MK-8931 60 mg for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment E: Placebo matching MK-8931 60 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receiving placebo matching MK-8931 60 mg for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8931</intervention_name>
    <description>MK-8931, capsules, at a dose of 12 or 40 mg, orally, once per day for 7 days</description>
    <arm_group_label>Treatment A: MK-8931 12 mg</arm_group_label>
    <arm_group_label>Treatment B: MK-8931 40 mg</arm_group_label>
    <arm_group_label>Treatment D: MK-8931 60 mg</arm_group_label>
    <other_name>SCH 900931</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules, orally, once per day for 7 days</description>
    <arm_group_label>Treatment C: Placebo matching MK-8931 12 mg or 40 mg</arm_group_label>
    <arm_group_label>Treatment E: Placebo matching MK-8931 60 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Body Mass Index (BMI) between 18 and 35

          -  Mild to moderate Alzheimer's Disease (AD)

          -  Clear history of cognitive and functional decline over at least one year that is
             either documented in medical records, or documented by history from an informant who
             knows the subject well

          -  Magnetic Resonance Image (MRI) scan consistent with a diagnosis of AD

          -  Ability to read at a 6th grade level and history of academic achievement and/or
             employment sufficient to exclude mental retardation

          -  If applicable, on a stable dose of an acetylcholinesterase inhibitor and/or memantine
             for at least the last 3 months before Screening, and willing to remain on the same
             dose for the duration of the trial

          -  Reliable trial partner/caregiver

          -  Willing to provide a blood sample for Apolipoprotein E (APOE) genotyping

          -  In general good health (other than AD)

          -  Participant capable of conceiving and/or participant with partner capable of
             conceiving willing to use a medically acceptable form of contraception during the
             trial and for 3 months after stopping the medication

        Exclusion criteria:

          -  History (within 2 years of the prestudy visit) or current evidence of any neurological
             or neurodegenerative disorder other than AD that is associated with transient or
             sustained alterations in cognition

          -  Clinically significant abnormalities in serum vitamin B12, folate, thyroid stimulating
             hormone (TSH) or thyroxin 4 (T4). Vitamin B12 or thyroid replacement therapy must with
             stable dose for at least 2 months prior to screening visit

          -  One or more pre-existing risk factors for Torsades de Pointes: New York Heart
             Association (NYHA) Functional Classification II through IV heart failure; Familial
             Long QT Syndrome; or Uncorrected hypokalemia

          -  Any surgical or medical condition which might significantly alter the absorption,
             distribution, metabolism or excretion of any drug

          -  History of spinal cord compression or any other current abnormalities in the lumbar
             region (skin infection, developmental abnormalities in lower spine, etc.)

          -  History of any infectious disease within 4 weeks prior to drug administration

          -  Human immunodeficiency virus (HIV) positive

          -  History of hepatitis or liver disease within 6 months of screening

          -  History of psychiatric or personality disorders

          -  Evidence of suicidality or is at risk for self-harm or harm to others

          -  History of seizures or epilepsy or anticonvulsant use within the last 5 years before
             Screening

          -  History of alcohol or drug abuse in the past 2 years

          -  Donation of blood in the past 60 days

          -  Previously received the study drug

          -  Currently participating in another clinical study or have participated in a clinical
             study (e.g., laboratory or clinical evaluation) within 30 days of baseline

          -  Member of the study staff or family members of the study staff

          -  Demonstrated allergic reactions (e.g., food, drug, atopic reactions or asthmatic
             episodes)

          -  History of malignancy occurring within the 5 years immediately before Screening,
             except for a subject who has been adequately treated for basal cell or squamous cell
             skin cancer, in situ cervical cancer, localized prostate carcinoma; or has undergone
             potentially curative therapy with no evidence of recurrence for ≥1 year post-therapy,
             and deemed at low risk for recurrence by her/his treating physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2011</study_first_submitted>
  <study_first_submitted_qc>December 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2011</study_first_posted>
  <last_update_submitted>October 22, 2015</last_update_submitted>
  <last_update_submitted_qc>October 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

